Hot Stocks

Hot stocks are not about hype. They emerge when powerful themes, policy shifts, and capital flows converge. InvestorPlace analysts track fast-moving market narratives, especially in technology, AI, and infrastructure, to identify stocks drawing outsized attention and explain what is really driving those moves.

The Crux of Marissa Mayer’s Problem at Yahoo

Her content strategy will be the key decision -- and it's tough. Does she expand Yahoo's original content to woo advertisers at the risk of alienating partners?

Berkshire Hathaway’s Premium: Confidence

Berkshire Hathaway shares have marched to 52-week highs as investors continue to believe in the succession preparation efforts of Warren Buffett.

Coca-Cola Is Starting to Sweat

Rising costs weighed on Coca-Cola's bottom line for Q2, and while KO still looks good down the road, short-term headwinds shouldn't be ignored.

Shorts Are Piling Onto These 3 Companies

A shaky earnings season could be good news for the shorts. Here are three companies really getting the stink-eye from investors right now.

Grading 6 Defense Contractors After the Farnborough Air Show

Looming defense cuts mean investors have to chose carefully. Here's how the sector's top players stack up now that the results of this year's air show are in.

Cure TV’s Nuttiness With a la Carte Pricing

Industry battles over carriage fees, such as the Dish-Viacom brawl, mask a bigger issue. Why should consumers pay for channels they don't want?

9 Biotech Buyout Players to Watch

The deal between Human Genome Sciences and GlaxoSmithKline is just the most recent of big pharma buyouts -- and these biotech players could be next.

Retail Results Spoil the Day — Monday’s IP Market Recap

A disappointing retail report and mixed results for Citigroup's second quarter weighed on markets Monday, though M&A news sparked life into pharma.

Gold, Silver Lack Luster on Monday

Gold futures traded flat and silver showed marginal losses Monday as investors wait for Bernanke to speak this week in Washington.

HGSI Holdout Proves Profitable — for Bagels

Joint pharmaceutical developers Human Genome and GlaxoSmithKline agreed to a sweetened $14.25/share offer for HGSI, cheering Rockville-area diners.

Citigroup: Too Big to Grow?

Yes, its balance sheet is stronger, and the worst may be over. But the bank's global sprawl is hampering revenue and profits, and it's hard to see past that.

GlaxoSmithKline to Pay $3.6B for Human Genome Sciences

GlaxoSmithKline will pay $14.25 a share, a total of $3.6 billion, to acquire its long-term research partner Human Genome Sciences.

MasterCard and Visa Agree to $6B Fee Settlement

Under a proposed settlement with retailers, Mastercard, Visa and a number of banks will pay more than $6 billion and will cut processing fees for eight months.

The Target-Neiman Marcus Partnership Looks Like a Winner

The odd-sounding partnership with Neiman Marcus makes a lot more sense than people realize. Here's why it may be a savvy move for both retailers.

Merck Could Have a Home Run in Sight

Merck’s new drug odanacatib can be thanked for the stock's recent rally, but there are two questions that need to be answered.

Gold, Silver Climb to End Dismal Week on a High Note

Gold and silver futures closed sharply higher on Friday. Gold bullion showed significant gains as well.

Wells Fargo’s Record Profits Show Housing on the Mend

Wells Fargo posted all-time high quarterly profits thanks to better results in mortgages and retail banking -- good news for WFC, and for the market.

All Aboard the Bakken Shale Railroad Plays

The ever-growing need to move drilling material in and crude oil out by rail is creating a gusher of revenue for a select group of railroad companies.

JPMorgan Has a Cold, Not Pneumonia

JPMorgan Chase's second-quarter earnings and Friday's rally prove that everything is relative to expectations -- at least in the daily scrum of trading.